Small- and large-scale biosimulation applied to drug discovery and development.

Biosimulation uses mathematics to quantitatively represent the dynamics of biological systems and thereby analyze and predict system behavior. Biosimulations can be classified into two general categories: small-scale models designed to address a specific problem, and large-scale models of detailed regulatory mechanisms used to address a broad scope of questions. Both classes of biosimulations have been applied to problems important for drug discovery and development. Small-scale biosimulations have been particularly useful for interpreting clinical data and developing novel biomarkers. Large-scale biosimulations typically integrate a wide variety of data and can provide insights into how complex biological systems are regulated in both health and disease. Because large-scale biosimulations represent detailed regulatory mechanisms and their interactions, they can predict the overall clinical effect of modulating individual pathways or targets. In this mini-review, we describe several examples of how small- and large-scale biosimulations have been applied to problems important for drug development in diabetes, HIV, heart disease and asthma.

[1]  Denis Noble,et al.  A return to rational drug discovery: computer-based models of cells, organs and systems in drug target identification , 2000 .

[2]  R. Bergman.  Toward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach , 1989, Diabetes.

[3]  Denis Noble,et al.  Computational modelling of biological systems: tools and visions , 2000, Philosophical Transactions of the Royal Society of London. Series A: Mathematical, Physical and Engineering Sciences.

[4]  R N Bergman,et al.  Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. , 1987, The Journal of clinical investigation.

[5]  R. Winslow,et al.  Computational models of the failing myocyte: relating altered gene expression to cellular function , 2001, Philosophical Transactions of the Royal Society of London. Series A: Mathematical, Physical and Engineering Sciences.

[6]  Minimal model for determination of insulin sensitivity: repeatability in control and obese subjects. , 1994, Diabetes research and clinical practice.

[7]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[8]  Y. Z. Ider,et al.  Quantitative estimation of insulin sensitivity. , 1979, The American journal of physiology.

[9]  Claudio Cobelli,et al.  The hot IVGTT two-compartment minimal model: indexes  of glucose effectiveness and insulin sensitivity. , 1997, American journal of physiology. Endocrinology and metabolism.

[10]  Noble,et al.  Biological simulations in drug discovery. , 1999, Drug discovery today.

[11]  C Cobelli,et al.  Insulin sensitivity from meal tolerance tests in normal subjects: a minimal model index. , 2000, The Journal of clinical endocrinology and metabolism.

[12]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[13]  R N Bergman,et al.  The Insulin Sensitivity Index in Nondiabetic Man: Correlation Between Clamp-derived and IVGTT-derived Values , 1986, Diabetes.

[14]  S. Holgate,et al.  The Roles of Cells and Mediators in a Computer Model of Chronic Asthma , 2001, International Archives of Allergy and Immunology.

[15]  Seth Michelson,et al.  Chapter 27. Biosimulation: Dynamic modeling of biological systems , 2002 .

[16]  Richard Li-Xiang Ho,et al.  Biosystems modelling for in silico target validation: challenges to implementation , 2000 .

[17]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[18]  A. Perelson.  Modelling viral and immune system dynamics , 2002, Nature Reviews Immunology.

[19]  D. Noble.  Modeling the Heart--from Genes to Cells to the Whole Organ , 2002, Science.

[20]  R. Egan,et al.  Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti-IL-5 antibody. , 1995, American journal of respiratory cell and molecular biology.

[21]  R. Egan,et al.  Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. , 1993, The American review of respiratory disease.

[22]  M. Rewers,et al.  Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. , 1999, Diabetes care.

[23]  I. Godsland,et al.  Assessment of insulin sensitivity in man: a comparison of minimal model- and euglycaemic clamp-derived measures in health and heart failure. , 1994, Clinical science.

[24]  R. Egan,et al.  Effects of an antibody to interleukin-5 in a monkey model of asthma. , 1995, American journal of respiratory and critical care medicine.

[25]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[26]  Claudio Cobelli,et al.  The oral glucose minimal model: Estimation of insulin sensitivity from a meal test , 2002, IEEE Transactions on Biomedical Engineering.